Cited by 95Bone Metabolism and DiseasesEstrogen and related hormone effectsPlatelet Disorders and Treatments

Estrogen inhibits RANKL-stimulated osteoclastic differentiation of human monocytes through estrogen and RANKL-regulated interaction of estrogen receptor-α with BCAR1 and Traf6

Open access
Robinson, Lisa J., Yaroslavskiy, Beatrice B., Griswold, Reed D., Zadorozny, Eva V., Guo, Lida, Tourkova, Irina L., Blair, Harry C.·2009·Experimental Cell Research

Abstract

The effects of estrogen on osteoclast survival and differentiation were studied using CD14-selected mononuclear osteoclast precursors from peripheral blood. Estradiol at approximately 1 nM reduced RANKL-dependent osteoclast differentiation by 40-50%. Osteoclast differentiation was suppressed 14 days after addition of RANKL even when estradiol was withdrawn after 18 h. In CD14+ cells apoptosis was rare and was not augmented by RANKL or by 17-beta-estradiol. Estrogen receptor-alpha (ERalpha) expression was strongly down-regulated by RANKL, whether or not estradiol was present. Mature human osteoclasts thus cannot respond to estrogen via ERalpha. However, ERalpha was present in CD14+ osteoclast progenitors, and a scaffolding protein, BCAR1, which binds ERalpha in the presence of estrogen, was abundant. Immunoprecipitation showed rapid (approximately 5 min) estrogen-dependent formation of ERalpha-BCAR1 complexes, which were increased by RANKL co-treatment. The RANKL-signaling intermediate Traf6, which regulates NF-kappaB activity, precipitated with this complex. Reduction of NF-kappaB nuclear localization occurred within 30 min of RANKL stimulation, and estradiol inhibited the phosphorylation of IkappaB in response to RANKL. Inhibition by estradiol was abolished by siRNA knockdown of BCAR1. We conclude that estrogen directly, but only partially, curtails human osteoclast formation. This effect requires BCAR1 and involves a non-genomic interaction with ERalpha.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.yexcr.2009.01.014

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Estrogen stimulates osteoblasts and osteocytes to produce osteoprotegerin (OPG), which inhibits osteoclastogenesis.

    “Moreover, estrogen stimulates these bone cells to produce osteoprotegerin (OPG), a decoy receptor of RANK in osteoclast, thus inhibiting osteoclastogenesis [19, 155–159].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Robinson, L. J., Yaroslavskiy, B. B., Griswold, R. D., Zadorozny, E. V., Guo, L., Tourkova, I. L., & Blair, H. C.
Affiliations
University of Pittsburgh (US)
Corresponding author
Robinson, Lisa J.
Venue
Experimental Cell Research
Publisher
Elsevier BV
Published
2009-04
Volume
315
Issue
7
Pages
1287-1301
ISSN
0014-4827 (ISSN-L)
OpenAlex
W1992438132
Cited by
95
References
66
Citations by year
2026: 3 · 2025: 5 · 2024: 6 · 2023: 10 · 2022: 6 · 2021: 8 · 2020: 8 · 2019: 1 · 2018: 5 · 2017: 4 · 2016: 1 · 2015: 6 · 2014: 4 · 2013: 8 · 2012: 7
FWCI
2.69
Type
journal article
Language
en
Open access
Locations
  • Experimental Cell Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (AR053566, AR47700)
  • U.S. Department of Veterans Affairs
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
  • Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
Keywords
estrogen, estradiol, RANKL, osteoclastogenesis, estrogen receptor alpha, p130Cas, TRAF6, monocytes, non-genomic estrogen signaling, NF-κB, IκB phosphorylation, osteoclast precursors, apoptosis
MeSH terms
Animals, Cell Differentiation, Cell Survival, Cells, Cultured, Estrogens, Female, Humans, Monocytes, Osteoclasts, Signal Transduction, NF-kappa B, Lipopolysaccharide Receptors, RNA, Small Interfering, Estrogen Receptor alpha, TNF Receptor-Associated Factor 6, Crk-Associated Substrate Protein, RANK Ligand

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review